Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells

Abstract

Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.

Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: Preparation, in vitro optimization, ex vivo cytotoxicity & in vivo biodistribution utilizing radioiodinated zopiclone

“…The optimized formula (NLC-OP) was diluted with distilled water then 5 μL was put on carbon-coated 400-mesh copper grids. The grid was then treated with a drop of filtered 2% phosphotungistic acid (PTA stain), pH 7, and left to stain for 30–60 s and then examined under TEM ( Medina-Montano et al, 2022 ).…”

Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents

“…The nanoparticles had good stability, did not interact with plasma regulatory proteins in vitro, and were well tolerated with primary nonparenchymal hepatocytes. 210 Albumin nanoparticles have good biocompatibility and biodegradability, low immunogenicity, easy surface modification, and strong binding ability with drugs, genes and polypeptides, showing great application potential in targeted and controlled drug delivery. 211 Therefore, anti-fibrotic drug delivery systems based on albumin nanoparticles have also attracted widespread attention.…”

“…The nanoparticles had good stability, did not interact with plasma regulatory proteins in vitro , and were well tolerated with primary nonparenchymal hepatocytes. 210…”

Ippia Alba Essential Oil: A Promising Complementary Therapy for Breast Cancer

“…These therapies, frequently rooted in nature, hold the potential to alleviate side effects, improve treatment outcomes, and bolster the overall well‐being of breast cancer patients [15] . Amidst the myriad of natural substances under investigation, Lippia alba essential oil stands out as a promising candidate for complementary breast cancer therapy [16] …”